Interactions between Adipex-P and Ozempic
During treatment with phentermine (Adipex-P), your dosage requirement of semaglutide (Ozempic) or any other diabetic medications you are taking may change as you lose weight. It is important to monitor your blood sugar more frequently and adjust your diabetic regimen accordingly. If you experience symptoms of hypoglycemia such as headache, dizziness, confusion, or rapid heartbeat, inform your doctor. Make sure to inform your doctor about all medications, including vitamins and herbs, that you are using. Do not stop using any medications without consulting your doctor.
Switch to professional interaction data
Drug and Food Interactions
Using phentermine (Adipex-P) with alcohol can increase the risk of cardiovascular side effects such as increased heart rate, chest pain, or blood pressure changes. It may also lead to nervous system side effects like dizziness, drowsiness, depression, and difficulty concentrating. It is advisable to avoid or limit alcohol consumption while being treated with phentermine. Do not exceed the recommended dose of phentermine and avoid activities that require mental alertness until you know how the medication affects you. Inform your doctor about all medications, including vitamins and herbs, that you are using. Do not stop using any medication without consulting your doctor.
Switch to professional interaction data
Semaglutide (Ozempic) may affect the absorption of other orally taken medications. This can potentially impact the effectiveness and speed of action of those medications. If you have any concerns or questions, consult a healthcare provider. Contact your doctor if your symptoms worsen or your condition changes. Inform your doctor about all medications, including vitamins and herbs, that you are using. Do not stop using any medications without consulting your doctor.
Switch to professional interaction data
Therapeutic Duplication Warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.